Although NCT3480152 has a background of basic studies showing the importance of TCR affinity and tumor specific CD4+ T cells in tumor immunotherapy for HCC and metastatic liver tumors [159], and NCT03198546 has a background of successful suppression of HCC growth in the basic research [87], no clinical results have been reported to date for these trials. This evidence concerns the gene CD4 and neoplasm.